Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C
To access this article, please choose from the options below
Conflicts of interest The authors disclose the following: Prof. Massimo Colombo: consulting: Schering-Plough, Roche, Novartis, Vertex; grant and research support: Schering-Plough, Roche, Novartis, Vertex; advisory committees: Schering-Plough, Roche, Novartis, Vertex; speaking and teaching: Schering-Plough, Roche, Novartis, Vertex. The remaining authors disclose no conflicts.
PII: S0016-5085(09)01575-3
doi:10.1053/j.gastro.2009.08.071
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Do Differences in Pegylation of Interferon Alfa Matter? , 23 November 2009

